TITLE

Lipotoxicity impairs incretin signalling

AUTHOR(S)
Poitout, V.
PUB. DATE
February 2013
SOURCE
Diabetologia;Feb2013, Vol. 56 Issue 2, p231
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced insulin secretion in response to food ingestion in a glucose-dependent manner. This mechanism forms the basis for incretin-based therapies in type 2 diabetes. However, the insulinotropic effect of incretins is diminished in type 2 diabetic patients, due in part to reduced expression of incretin receptors as a consequence of glucotoxicity. In this issue of Diabetologia, Kang et al (DOI: ) provide evidence that in addition to glucotoxicity, lipotoxicity also affects incretin receptor expression and signalling in insulin-secreting cells and isolated islets. In animal models of diabetes, the authors show that co-administration of a lipid-lowering drug with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 agonist improved glucose tolerance and beta cell mass. These novel findings provide convincing support for the notion that restoring normal circulating lipid levels in type 2 diabetes might help improve the efficacy of incretin-based therapies.
ACCESSION #
84600902

 

Related Articles

  • CARDIOVASCULAR DISEASE AND DIABETES--CLINICAL AND TRANSLATIONAL.  // Diabetes;Jun 2014 Supplement, pA1 

    The article presents abstracts of studies related to cardiovascular disease and diabetes, which include the role of dipeptidyl peptidase (DPP)-IV in human cardiac progenitor cell survival in response to lipotoxicity, the link between a signal near FRMD4A and lower extremity arterial disease in...

  • Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Kang, Z.; Deng, Y.; Zhou, Y.; Fan, R.; Chan, J.; Laybutt, D.; Luzuriaga, J.; Xu, G. // Diabetologia;Feb2013, Vol. 56 Issue 2, p423 

    Aims/hypothesis: Type 2 diabetes mellitus is associated with reduced incretin effects. Although previous studies have shown that hyperglycaemia contributes to impaired incretin responses in beta cells, it is largely unknown how hyperlipidaemia, another feature of type 2 diabetes, contributes to...

  • Lipotoxic diseases of nonadipose tissues in obesity. Unger, R H; Orci, L // International Journal of Obesity & Related Metabolic Disorders;Nov2000 Supplement, Vol. 24, pS28 

    It is proposed that an important function of leptin is to confine the storage of triglycerides (TG) to the adipocytes, while limiting TG storage in nonadipocytes. Excess TG deposition in nonadipocytes leads to impairment of functions, increased ceramide formation, which triggers nitric...

  • Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.  // BMC Neuroscience;2012, Vol. 13 Issue 1, p33 

    The article discuses a study conducted to measure kinetics of incretin drugs of crossing the blood brain barrier, activation of incretin receptors and physiological effects in the brain on cell proliferation and neurogenesis. It is evident that incretin drugs enhances insulin signalling that...

  • Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Bergman, Michael // Endocrine (1355008X);Jun2013, Vol. 43 Issue 3, p504 

    Type 2 diabetes and other non-communicable diseases (NCD) are a growing public health challenge globally. An estimated 285 million people, corresponding to 6.4 % of the world's adult population has diabetes. This is expected to reach 552 million by 2030, 7.8 % of the adult population, with the...

  • Antiobesogenic effects of central GIPR antagonism. Yue, Jessica T. Y.; Lam, Tony K. T.; Yue, Jessica Ty; Lam, Tony Kt // Journal of Clinical Investigation;Sep2019, Vol. 129 Issue 9, p3532 

    Developing effective treatments for obesity and related metabolic disease remains a challenge. One logical strategy targets the appetite-regulating actions of gut hormones such as incretins. One of these incretins, glucose-dependent insulinotropic polypeptide (GIP), has garnered much attention...

  • Fatty old hearts: role of cardiac lipotoxicity in age-related cardiomyopathy. Drosatos, Konstantinos // Pathobiology of Aging & Age-related Diseases;2016, Vol. 6, p1 

    Age-related cardiomyopathy accounts for a significant part of heart failure cases. Imbalance of the energetic equilibrium of the heart along with mitochondrial dysfunction and impaired β-adrenergic receptor signaling contributes in the aggravation of cardiac function in the elderly. In this...

  • Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Cernea, Simona; Dobreanu, Minodora // Biochemia Medica;2013, Vol. 23 Issue 3, p266 

    Diabetes is a complex, heterogeneous condition that has beta cell dysfunction at its core. Many factors (e.g. hyperglycemia/glucotoxicity, lipotoxicity, autoimmunity, inflammation, adipokines, islet amyloid, incretins and insulin resistance) influence the function of pancreatic beta cells....

  • Nutrient-Induced Insulin Resistance in Human Skeletal Muscle. Krebs, M.; Roden, M. // Current Medicinal Chemistry;Apr2004, Vol. 11 Issue 7, p901 

    Nutrient excess is associated with reduced insulin sensitivity (insulin resistance) and plays a central role in the pathogenesis of type 2 diabetes. Recently, free fatty acids as well as amino acids were shown to induce insulin resistance by decreasing glucose transport / phosphorylation with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics